Targeted drug shows promise for Gene-Driven lung cancers

NCT ID NCT04084717

Completed Disease control Sponsor: University Health Network, Toronto Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests the drug crizotinib (XALKORI) in people with advanced non-small cell lung cancer that has spread and carries a change in the ROS1 or MET gene. Participants take crizotinib by mouth twice daily. The study aims to see how well the drug shrinks tumors and delays cancer growth, while also tracking side effects and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: crizotinib (XALKORI)
What this could lead to: If successful, this could provide an effective treatment option for people with advanced lung cancer driven by ROS1 or MET gene changes.
What could go wrong: This is a small, early-phase study, so results may not apply to all patients. Crizotinib can cause side effects like nausea, vision problems, and liver issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MET ACTIVATING MUTATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MET ACTIVATING MUTATION MET AMPLIFICATION NON-SQUAMOUS NON-SMALL CELL LUNG CANCER ROS1 GENE REARRANGEMENT STAGE IV NON-SMALL CELL LUNG CANCER

Targeted drug shows promise for Gene-Driven lung cancers

Summary

What this could mean

Get notified about this study

Conditions

As listed by the trial registrant

Contacts and locations

Locations

More trials for these conditions